Author

David Pau

Observed names: D Pau, D. David Pau, D. Pau, D.L. Pau, David PAU, Pau, David

Observed institution: Roche (France)

ORCID: 0000-0001-7664-4521

Observed ORCID: 0000-0001-7664-4521

OpenAlex ID: A5112087884

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

2019 · Jean Darloy, Nicolas Segaud, et al. · Rheumatology and Therapy · 17

PDF

Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study

2022 · Eric Manchon, David Laplaud, et al. · Multiple Sclerosis and Related Disorders · 15

PDF

Comparison of anonymization techniques regarding statistical reproducibility

2025 · David Pau, Camille Bachot, et al. · PLOS Digital Health · 8

PDF

FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010

2021 · Didier Debieuvre, Charles Dayen, et al. · Lung Cancer · 8

One-third of patients are low-adherent to methotrexate for rheumatoid arthritis at the initiation of a first biologic. A cross-sectional study investigating adherence rate and factors

2020 · Catherine Beauvais, David Pau, et al. · Joint Bone Spine · 7

“Doctor, can I have less frequent injection with highly efficient treatment?” A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study)

2019 · Cécile Vigneau, Gabriel Choukroun, et al. · Néphrologie & Thérapeutique · 7

Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial.

2011 · R. Rouzier, E. Lambaudie, et al. · Journal of Clinical Oncology · 5

Capability and accuracy of usual statistical analyses in a real-world setting using a federated approach

2024 · Romain Jégou, Camille Bachot, et al. · PLoS ONE · 3

Impact des comorbidités sur la stabilité de l’hémoglobine chez des patients insuffisants rénaux chroniques en hémodialyse, traités par CERA en pratique courante : l’étude MIRIADE

2019 · Luc Frimat, Mustapha Amirou, et al. · Néphrologie & Thérapeutique · 3

PDF

Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer

2025 · Cyril Esnault, Louise Baschet, et al. · BMC Medical Research Methodology · 2

Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study

2025 · Xavier Moisset, Grégoire Mercier, et al. · Multiple Sclerosis and Related Disorders · 2

PDF

Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)

2024 · Cécile Donzé, Claude Mekies, et al. · Multiple Sclerosis and Related Disorders · 2

PDF

2020 · L. Greillier, V. Tuzelet, et al. · Value in Health · 2

Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study

2018 · Pierre Feugier, Pauline Brice, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2

Data Mining Based On Real World Data In Chronic Kidney Disease Patients Not On Dialysis: The Key Role Of Early Hemoglobin Levels Control

2015 · L Frimat, D Pau, et al. · Value in Health · 2

Economic Evaluation and Added Value for Stakeholders of Switching From Rituximab Intravenous Injection to Rituximab Subcutaneous Injection In France

2015 · N Plommet, D Pau, et al. · Value in Health · 2

Evaluating the statistical utility and information loss in the transformation of a real-world oncology database from CDISC-SDTM to OMOP-CDM

2025 · A. Lambert, C. Castagne, et al. · ESMO Real World Data and Digital Oncology · 1

PDF

Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France

2025 · Grégoire Mercier, David Pau, et al. · Journal of Multiple Sclerosis and Neuroimmunology · 1

PDF

PCR13 Preliminary Analysis of the Multiple Sclerosis Autonomy Scale (MSAS) Questionnaire Evaluating Patient Autonomy in Multiple Sclerosis (MS)

2024 · C. Donze, C. Mekies, et al. · Value in Health · 1

PDF

RWD45 Real-World Data to Support Surrogate Endpoint Evaluation for Health Technology Assessment

2022 · J Dupin, K Thokagevistk, et al. · Value in Health · 1

PDF

Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.

2016 · Marie-Pierre Chenard, Eric Anger, et al. · Journal of Clinical Oncology · 1

Results of a Study Using a Tablet PC to Collect PROs in Elderly Population

2013 · D. Pau, L. Nguyen, et al. · Value in Health · 1

Results of a study evaluating patient's perception regarding their erythropoiesis stimulating agent treatment in chronic kidney disease using a choice based conjoint analysis

2013 · D. Pau, G. Choukroun, et al. · Value in Health · 1

Determination of the Minimal Clinically Important Difference exploring distribution-based methods: Case study of the MSAS scale in Multiple Sclerosis

2026 · Emma Ganguillin, Cécile Donzé, et al.

Healthcare Resource Utilization and Costs of naïve patients initiating ocrelizumab versus other High-Efficacy Therapies for Multiple Sclerosis: results from the French Real-World OLIDIA study

2026 · Jonathan Ciron, Laurent Suchet, et al.

Works count: 112

Citation count: 94

H-index: 6

I10-index: 2